Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial

<p><strong>Background: </strong>The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7% efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-blinded, placebo-controlled trial in the United Kingdom. The protocol was amended...

Full description

Bibliographic Details
Main Authors:	Heath, PT, Galiza, EP, Baxter, DN, Boffito, M, Browne, D, Burns, F, Chadwick, DR, Clark, R, Cosgrove, CA, Galloway, J, Goodman, AL, Heer, A, Higham, A, Iyengar, S, Jeanes, C, Kalra, PA, Kyriakidou, C, Bradley, JM, Munthali, C, Minassian, AM, McGill, F, Moore, P, Munsoor, I, Nicholls, H, Osanlou, O, Packham, J, Pretswell, CH, San Francisco Ramos, A, Saralaya, D, Sheridan, RP, Smith, R, Soiza, RL, Swift, PA, Thomson, EC, Turner, J, Viljoen, ME, Fries, L, Cho, I, McKnight, I, Glenn, G, Rivers, EJ, Robertson, A, Alves, K, Smith, K, Toback, S
Format:	Journal article
Language:	English
Published:	Oxford University Press 2022

Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial

Similar Items